Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Fuji Pharma Co., Ltd. (FUP) Stock Price & Analysis

0 Followers

FUP Stock Chart & Stats

€10.50€0.00(0.00%)
At close: 5:30 PM GMT+1
€9€10€11€12Nov 19Feb 5
Day’s Range
EUR 10.50 - EUR 10.50
52-Week Range
EUR 8.70 - EUR 13.60
Previous Close
EUR 10.50
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 277.78M
Enterprise Value
EUR 71.00B
Total Cash (Recent Filing)
EUR 9.95B
Total Debt (Recent Filing)
EUR 28.89B
Price to Earnings (P/E)
15.7
Beta
0.35
Next Earnings
Nov 10, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
2.12%

Bulls Say, Bears Say

Bulls Say

Consistent Revenue Growth

Fuji Pharma's ~17% revenue growth reflects sustained product demand and commercial execution in its prescription business. Durable top-line expansion supports reinvestment in R&D and manufacturing scale, underpinning multi-quarter growth prospects independent of short-term market swings.

Diversified Business Model (Branded + CDMO)

A dual model—branded prescription sales plus CDMO manufacturing—smooths revenue volatility and monetizes manufacturing assets. Contract manufacturing provides recurring fee-based income and secular demand from pharma outsourcing, enhancing resilience across product lifecycle stages.

Improving Free Cash Flow

Improved free cash flow and a stronger FCF-to-net-income ratio increase financial flexibility for capex, debt servicing, or shareholder returns. Strengthening cash conversion is a durable indicator of operational health and reduces reliance on external financing.

Bears Say

Rising Leverage

An increasing debt-to-equity trend raises financial risk and interest obligations, lowering buffer against revenue or margin shocks. Sustained leverage growth can constrain capital allocation, limit strategic flexibility, and amplify downside during cyclical or regulatory headwinds.

Margin Volatility

Recent declines and volatility in EBIT and net margins suggest pressure from pricing, mix, or cost increases. Persistent margin variability undermines profit predictability, reducing the firm's ability to consistently fund R&D, manufacturing upgrades, or absorb higher financing costs.

Weak Operating Cash Conversion

Operating cash lagging net income implies possible working capital strain or reliance on non-cash earnings. Over time this can impair self-funding for growth and force incremental borrowing or equity issuance, especially problematic given the company’s rising leverage.

Fuji Pharma Co., Ltd. News

FUP FAQ

What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was €8.70 and its highest was €13.60 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is €277.78M.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on Aug 06, 2026. The company reported €0.245 earnings per share for the quarter.
Is Fuji Pharma Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. does not currently pay dividends.
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,541,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of €0.245 in its last earnings report. Following the earnings report the stock price went up 2.02%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in DE:FUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology